Diligence memo · auto-generated · as of July 2, 2026

Chirality Biosciences, Inc.

Chirality Biosciences, Inc. looks over-valued against its niche peers and is active on financing cadence.

WatchModeled above niche peers — entry today likely prices in growth not yet evidenced in the filings.

Businessfiled

Chirality Biosciences, Inc. operates in Biotech / Pharma, based in FARMINGDALE.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Chirality Biosciences, Inc. has raised $3.1M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).

Largest single filing: $3.1M on 2025-10-17.

Most recent recorded round closed around 2025-10-17.

Valuation (modeled)modeled

Provath models Chirality Biosciences, Inc. at approximately $7.4M (range $2.3M–$14M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Over-valued. Modeled value is 2.09× the median modeled value of Seed Biotech / Pharma companies in 2025–2027 (5 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Last raise 8 mo ago; this sector typically re-raises about every 15 months.

Raising on or ahead of the sector's normal rhythm.

Comparablesmixed

Capital scale ranks ahead of 43% of Biotech / Pharma peers (227 compared).

Modeled value ranks above 30% of those peers.

Closest niche peers: Pluto Biosciences, Inc., Spearhead Bio, Inc., PharmaWaste Ventures, LLC, Catch Bio, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Modeled above niche peers — valuation risk on entry.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.